Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Cadranel

Showing results (31-40 of 329) with videos related to

Pageof 33
Sort By:
Current Drug Targets|October 21, 2009
The role of pemetrexed in lung adenocarcinoma, mixed subtype with bronchioloalveolar carcinoma featuresMichael Duruisseaux, Jacques Cadranel, Maurice Pérol, et al.
Respiration; International Review of Thoracic Diseases|July 5, 2002
Nodular densities after HAART introduction in an AIDS patientJean-Marc Naccache, Marie Wislez, Charles Mayaud, et al.
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectivesEtienne Giroux-Leprieur, Vincent Fallet, Jacques Cadranel, et al.
The European Respiratory Journal|October 29, 2021
Targeted adjuvant therapy in non-small cell lung cancer: trick or treat?Lizza E L Hendriks, Jan van Meerbeeck, Jacques Cadranel
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2026
ILD with Datopotamab Deruxtecan combinations: A warning signal we should not ignoreElvire Pons-Tostivint, Louis Maurier, Jaafar Bennouna, et al.
European Journal of Human Genetics : EJHG|September 27, 2023
Emerging cancer risks in BRCA2 pathogenic germline variant carriersPatrick R Benusiglio, Antoine Dardenne, Vincent Fallet, et al.
Presse Medicale (Paris, France : 1983)|March 23, 2011
[Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies]Marie Wislez, Armelle Lavolé, Valérie Gounant, et al.
Bulletin Du Cancer|February 27, 2017
[Crizotinib for ROS1-rearranged non-small cell lung cancer patients]Charlotte Domblides, Martine Antoine, Armelle Lavole, et al.
Bulletin Du Cancer|June 21, 2012
[Management of crizotinib, a new individualized treatment]Vincent Fallet, Cécile Toper, Martine Antoine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2022
Do Female <i>BRCA2</i> Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?Vincent Fallet, Mateo Sanchis-Borja, Patrick R Benusiglio, et al.
Pageof 33

Showing results (31-40 of 329) with videos related to

Sort By:
Pageof 33
Current Drug Targets|October 21, 2009
The role of pemetrexed in lung adenocarcinoma, mixed subtype with bronchioloalveolar carcinoma featuresMichael Duruisseaux, Jacques Cadranel, Maurice Pérol, et al.
Respiration; International Review of Thoracic Diseases|July 5, 2002
Nodular densities after HAART introduction in an AIDS patientJean-Marc Naccache, Marie Wislez, Charles Mayaud, et al.
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectivesEtienne Giroux-Leprieur, Vincent Fallet, Jacques Cadranel, et al.
The European Respiratory Journal|October 29, 2021
Targeted adjuvant therapy in non-small cell lung cancer: trick or treat?Lizza E L Hendriks, Jan van Meerbeeck, Jacques Cadranel
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2026
ILD with Datopotamab Deruxtecan combinations: A warning signal we should not ignoreElvire Pons-Tostivint, Louis Maurier, Jaafar Bennouna, et al.
European Journal of Human Genetics : EJHG|September 27, 2023
Emerging cancer risks in BRCA2 pathogenic germline variant carriersPatrick R Benusiglio, Antoine Dardenne, Vincent Fallet, et al.
Presse Medicale (Paris, France : 1983)|March 23, 2011
[Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies]Marie Wislez, Armelle Lavolé, Valérie Gounant, et al.
Bulletin Du Cancer|February 27, 2017
[Crizotinib for ROS1-rearranged non-small cell lung cancer patients]Charlotte Domblides, Martine Antoine, Armelle Lavole, et al.
Bulletin Du Cancer|June 21, 2012
[Management of crizotinib, a new individualized treatment]Vincent Fallet, Cécile Toper, Martine Antoine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2022
Do Female <i>BRCA2</i> Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?Vincent Fallet, Mateo Sanchis-Borja, Patrick R Benusiglio, et al.
Pageof 33